Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients

Renal Failure

Volumn 30, Issue 4, 2008, Pages 407-410

  Dogan, Ekrem ^a   Erkoc, Reha ^b   Sayarlioglu, Hayriye ^a   Soyoral, Yasemin ^b   Dulger, Haluk ^b  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^b YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Calcidiol; Cholecalciferol; Chronic kidney diseases; Uremic bone diseases

Indexed keywords

ALKALINE PHOSPHATASE; COLECALCIFEROL; CREATININE; PARATHYROID HORMONE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROL GROUP; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIFEDIOL; CHOLECALCIFEROL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 45749147117     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220801964210     Document Type: Article

References (11)

1. Ghazali A, Fardellone P, Pruna A. Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int. 1999;55:2169-2177.
2. Sprague SM, Lerma E, McCormmick D, Abraham M, et al. Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001;38:S51-S56.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S201.
4. Levey AS, Coresh J, Balk E. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
5. Rickers H, Christiansen C, Christensen P, et al. Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron. 1985;39:267-271.
6. Koenig KG, Lindberg JS, Zerwekh JE, et al. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int. 1992;41:161-165.
7. Chapuy MC, Pamphile R, Paris E. Combined calcium and vitamin D3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II study. Osteoporos Int. 2002;13:257-264.
8. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351:805-806.
9. Wong J, Tran J, Thomas D, et al. Hypovitaminosis D (HVD) exacerbates secondary hyperparathyroidism early in the course of chronic kidney disease. Proc. Endocrine Society's 84th Annual Meeting, P2-557, June 19-22, 2002, p. 450.
10. LaClair RE, Hellman RN, Karp SN. Prevalence of calcidiol deficiency in CKDA cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45:1026-1033.
11. Holick MF. Vitamin D deficiency in CKD: Why should we care? Am J Kidney Dis. 2005;45(6):1026-1033.